Drug recall · October 2, 2019
Natpara recall
Why: Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Natpara (parathyroid hormone) for Injection, 75 mcg, 2 pack medication cartridges, Rx only, For subcutaneous use only, Manufactured for: Shire-NPS Pharmaceuticals, Inc., Lexington, MA NDC 68875-0204-02
- Lots / codes
06628462, exp 5/31/2020 06651000, exp 9/30/2020 06661659, exp 6/30/2020 07110125, 07301073, exp 10/31/2020 07200435, 7/31/2020 07482211, exp 12/31/2020 07630714, exp 3/31/2021 NX170002DA, exp 12/31/2019 NX17004DA, exp 3/31/2020 NX17007DA, NX17007DB, NX17008DA exp 4/30/2020 NX17010DA, NX17012DA, exp 6/30/2020
- Quantity
- 15,075
- Company
- Shire Human Genetic Therapies, Inc., Lexington, MA
- Distribution
- Product was distributed throughout the United States.
- Initiated
- September 12, 2019 · Voluntary: Firm initiated
- Classified
- October 1, 2019
- Reported
- October 2, 2019
- Ended
- March 23, 2021
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.